What a great day yesterday at CAR-TCR London! 27 Feb, 2025
Thank you to our panelists for an in-depth conversation on Novel CARs and New Applications – Implications for CMC, Process, and Analytics.
Our CSO Farzin Farzaneh, PhD, and
John Maher, CSO, Leucid Bio
Renaud VAILLANT, CEO, Alaya.bio
Paul S Carter, Sr. Director, MSAT, Quell Therapeutics
CAR-TCR Summit Series Europe, London
25-27 Feb
Contact us to discuss how our viral vector expertise can accelerate your therapy from lab to life. Makis Sigalas, PhD
#CARTCRSummit #CellTherapy #GeneTherapy #AdvancedTherapies
#BiotechInnovation #CGT #CARTCR #CARTCellTherapy #TCRTherapy
#Immunotherapy #CancerResearch